Their OGI stock forecasts range from $2.25 to $5.30. On average, they anticipate OrganiGram's share price to reach $3.43 in the next twelve months. This suggests a possible upside of 264.3% from the stock's current price.
Full Answer
What is the target price for organigram stock?
Their forecasts range from $2.25 to $5.30. On average, they expect OrganiGram's share price to reach $3.69 in the next year. This suggests a possible upside of 138.3% from the stock's current price. View analysts' price targets for OrganiGram or view top-rated stocks among Wall Street analysts. Who are OrganiGram's key executives?
Who bought organigram stock?
OGI stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. How do I buy shares of OrganiGram? Shares of OGI can be purchased through any online brokerage account.
Is there an upside for organigram stock?
According to analysts' consensus price target of $3.69, OrganiGram has a forecasted upside of 134.5% from its current price of $1.58. OrganiGram has only been the subject of 4 research reports in the past 90 days. OrganiGram has received 194 “outperform” votes. (Add your “outperform” vote.) OrganiGram has received 76 “underperform” votes.
How much is an Ogi stock worth?
One share of OGI stock can currently be purchased for approximately $1.55. How much money does OrganiGram make? OrganiGram has a market capitalization of $464.77 million and generates $62.43 million in revenue each year. The company earns $-103.09 million in net income (profit) each year or ($0.30) on an earnings per share basis.
Will OrganiGram stock go up?
The 10 analysts offering 12-month price forecasts for OrganiGram Holdings Inc have a median target of 2.02, with a high estimate of 2.66 and a low estimate of 1.14. The median estimate represents a +92.00% increase from the last price of 1.05.
Is OrganiGram a Buy Sell or Hold?
OrganiGram has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 4 buy ratings, 3 hold ratings, and 1 sell rating.
Is OrganiGram a buy?
OrganiGram has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Does OrganiGram stock pay dividends?
Organigram Holdings (NASDAQ: OGI) does not pay a dividend.
Is Ogi a buy Zacks?
How good is it? See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return2Buy18.15%3Hold9.70%4Sell5.35%5Strong Sell2.45%2 more rows
Is OHI stock a buy or sell?
For example, a stock trading at $35 with earnings of $3 would have an earnings yield of 0.0857 or 8.57%. A yield of 8.57% also means 8.57 cents of earnings for $1 of investment....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Will Tilray go up?
Tilray's stock is expected to rise in December 2022. The uptrend prediction has a price objective of $5.92119. There is a maximum goal price of $7.22 and a minimum target price of $5.28.
How many outstanding shares does OGI have?
Share StatisticsAvg Vol (3 month) 33.91MShares Outstanding 5313.71MImplied Shares Outstanding 6N/AFloat 8252.43M% Held by Insiders 118.66%7 more rows
Is Sundial growers a good stock to buy?
Sundial Growers is a strong company with good prospects for continued growth. But, its stock price has been incredibly low the past year or so. Sundial is a good company to invest in for the long-term.
Is organigram a good long term investment?
Organigram's Low Product Costs and Solid Capacity But interestingly, it appears to be performing much better overall. Its annual production rate lies around 62,000 kilograms, and by fall this year, the company's total capacity is expected to be at 113,000 kilograms.
Is Sundial growers a good stock to buy?
Sundial Growers is a strong company with good prospects for continued growth. But, its stock price has been incredibly low the past year or so. Sundial is a good company to invest in for the long-term.
Will Tilray go up?
Tilray's stock is expected to rise in December 2022. The uptrend prediction has a price objective of $5.92119. There is a maximum goal price of $7.22 and a minimum target price of $5.28.
Should I buy or sell OrganiGram stock right now?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 3 hold ratings a...
What is OrganiGram's stock price forecast for 2022?
7 equities research analysts have issued twelve-month target prices for OrganiGram's shares. Their forecasts range from $2.25 to $5.30. On average,...
How has OrganiGram's stock performed in 2022?
OrganiGram's stock was trading at $1.75 at the start of the year. Since then, OGI stock has decreased by 40.0% and is now trading at $1.05. View t...
When is OrganiGram's next earnings date?
OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, July 12th 2022. View our earnings forecast for OrganiGram .
How were OrganiGram's earnings last quarter?
OrganiGram Holdings Inc. (NASDAQ:OGI) announced its quarterly earnings results on Tuesday, April, 12th. The company reported ($0.02) earnings per s...
Who are OrganiGram's key executives?
OrganiGram's management team includes the following people: Mr. Derrick W. West CPA , CPA, (CA), Chief Financial Officer (Age 55, Pay $241.72k)...
Who are some of OrganiGram's key competitors?
Some companies that are related to OrganiGram include BELLUS Health (BLUSF) , Madrigal Pharmaceuticals (MDGL) , Lyell Immunopharma (LYEL) , Cry...
What other stocks do shareholders of OrganiGram own?
Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB) , (CGC) ,...
What is OrganiGram's stock symbol?
OrganiGram trades on the NASDAQ under the ticker symbol "OGI."
About OrganiGram
OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.
Headlines
CGC: Canopy Growth vs. OrganiGram: Which Cannabis Stock Is a Better Buy? - StockNews.com
OrganiGram (NASDAQ:OGI) Frequently Asked Questions
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OrganiGram stock.
How much did Organigram invest in British tobacco?
On Monday, Organigram said it received an investment of $221 million Canadian ($177 million) from British American Tobacco ( NYSE:BTI). Under the terms of the deal, the two companies will share intellectual property and work together to develop new cannabis products, with an initial focus on CBD (cannabidiol).
Is Organigram a competitor?
British American Tobacco's investment places Organigram in a strong competitive position . It will help to strengthen the marijuana producer's balance sheet and potentially allow it to acquire one of its smaller rivals. The partnership should also help to bolster Organigram's international expansion prospects, by allowing it to plug into British American Tobacco's global distribution network.
Why Canopy Growth, Hexo, and OrganiGram Are Slumping Today
Canadian marijuana stocks are reversing course Monday after last week's industrywide surge higher.
Despite Market Headwinds, Organigram Is Making Progress Toward Its Goals
Like most marijuana stocks, Organigram (NASDAQ: OGI) has underperformed the market in recent years, but in its most recent fiscal first quarter, the company showed off strong growth and a narrowing loss on the bottom line. In this episode of "Beat and Raise" recorded on Jan.
Why Marijuana Stocks Are Smoking Hot Today
Marijuana stocks are having a terrific Tuesday, with OrganiGram Holdings (NASDAQ: OGI) shares gaining 8% as of 11:35 a.m. ET, Aurora Cannabis (NASDAQ: ACB) up a strong 9%, and Hexo Corp (NASDAQ: HEXO) leading the whole pack higher with a 12.8% gain. You can thank Senate Majority Leader Chuck Schumer for that.
The cannabis company is making some new goodies available to medical marijuana users
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
What happened
Shares of Organigram Holdings ( NASDAQ:OGI) were flying on Thursday after the company said it was rolling out its "cannabis 2.0" products to its medical marijuana customers.
So what
Cannabis 2.0 is a term used to describe second-generation marijuana products such as edibles and beverages, as opposed to cannabis 1.0 products like dried flower.
Now what
Cannabis-infused products are regarded as a potential panacea for the ailing marijuana industry. They tend to be higher-margin items, and therefore are expected to help cannabis companies like Organigram improve their profitability.